A group of the D-related HLA antigens found to differ from the DR antigens in genetic locus and therefore inheritance. These antigens are polymorphic glycoproteins comprising alpha and beta chains and are found on lymphoid and other cells, often associated with certain diseases.
A malabsorption syndrome that is precipitated by the ingestion of foods containing GLUTEN, such as wheat, rye, and barley. It is characterized by INFLAMMATION of the SMALL INTESTINE, loss of MICROVILLI structure, failed INTESTINAL ABSORPTION, and MALNUTRITION.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Compounds and molecular complexes that consist of very large numbers of atoms and are generally over 500 kDa in size. In biological systems macromolecular substances usually can be visualized using ELECTRON MICROSCOPY and are distinguished from ORGANELLES by the lack of a membrane structure.
A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.
Plasma glycoprotein member of the serpin superfamily which inhibits TRYPSIN; NEUTROPHIL ELASTASE; and other PROTEOLYTIC ENZYMES.
The class of heavy chains found in IMMUNOGLOBULIN A. They have a molecular weight of approximately 58 kDa and contain about 470 amino acid residues arranged in four domains and an oligosaccharide component bound covalently to their Fc fragment constant region.
One of the two major pharmacological subdivisions of adrenergic receptors that were originally defined by the relative potencies of various adrenergic compounds. The alpha receptors were initially described as excitatory receptors that post-junctionally stimulate SMOOTH MUSCLE contraction. However, further analysis has revealed a more complex picture involving several alpha receptor subtypes and their involvement in feedback regulation.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
Hypoxia-inducible factor 1, alpha subunit is a basic helix-loop-helix transcription factor that is regulated by OXYGEN availability and is targeted for degradation by VHL TUMOR SUPPRESSOR PROTEIN.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.
Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.
The rate dynamics in chemical or physical systems.
The parts of a macromolecule that directly participate in its specific combination with another molecule.
Transmembrane proteins that form the beta subunits of the HLA-DQ antigens.
Proteins prepared by recombinant DNA technology.
The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells.
T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognize antigens only when presented in association with major histocompatibility (MHC) molecules.
Normal adult human hemoglobin. The globin moiety consists of two alpha and two beta chains.
Human immune-response or Class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-D locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune etiology.
Receptors present on activated T-LYMPHOCYTES and B-LYMPHOCYTES that are specific for INTERLEUKIN-2 and play an important role in LYMPHOCYTE ACTIVATION. They are heterotrimeric proteins consisting of the INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT, the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT, and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN.
Genetic loci in the vertebrate major histocompatibility complex that encode polymorphic products which control the immune response to specific antigens. The genes are found in the HLA-D region in humans and in the I region in mice.

Major DQ8-restricted T-cell epitopes for human GAD65 mapped using human CD4, DQA1*0301, DQB1*0302 transgenic IA(null) NOD mice. (1/153)

The 65KD isoform of GAD is considered to be a major target autoantigen in many humans with autoimmune prediabetes or diabetes. The major histocompatibility complex class II allele DQA1*0301, DQB1*0302, which encodes HLA-DQ8, confers susceptibility to type 1 diabetes and occurs in up to 80% of affected individuals. To map T-cell epitopes for GAD65 restricted to the diabetes-associated DQ8 heterodimer, we generated transgenic NOD mice expressing HLA-DQ8 and human CD4 while having the mouse class II gene (IA(beta)) deleted. These mice were immunized with full-length purified recombinant GAD65, and the fine specificity of T-cell responses was mapped by examining recall responses of bulk splenocytes to an overlapping set of 20-mer peptides encompassing the entire GAD65 protein. Four different peptides (P121-140, P201-220, P231-250, and P471-490) gave significant T-cell recall responses. P201-220 and P231-250 have been shown previously to bind DQ8, whereas the other two peptides had been classified as nonbinders. Interestingly, the peptide giving the greatest response (P201-220) encompasses residues 206-220 of GAD65, a region that has been shown to be a dominant T-cell epitope in wild-type IA(g7) NOD mice. Overlap in this T-cell epitope likely reflects structural similarities between DQ8 and IA(g7). The fine specificity of antibody responses in the GAD65-immunized mice was also examined by testing the antisera by enzyme-linked immunosorbent assay (ELISA) against the same overlapping set of peptides. The two dominant B-cell epitopes were P361-380 and P381-400; P121-140 and P471-490 appeared to correspond to both B- and T-cell epitopes. Although the NOD human CD4, DQ8, IA(null) transgenic mice generated in these studies do not develop autoimmune diabetes either spontaneously or after cyclophosphamide treatment, they can be used to map DQ8-restricted T-cell epitopes for a variety of human islet autoantigens. They can also be used to test T-cell-specific reagents, such as fluorescently labeled DQ8 tetramers containing GAD65 peptides or other beta-cell peptides, which we believe will be useful in analyzing human immune responses in diabetic and prediabetic patients.  (+info)

Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis. (2/153)

The interaction of the T-cell receptor with the major histocomatibility complex (MHC)-peptide complex is central to T-cell activation. Variation in the nature of the peptide bound within the groove of the MHC molecule may result in an altered T-cell response. Because some naturally processed peptides bound within the groove of the class II MHC molecule are derived from the MHC molecules themselves, we studied the inhibitory effects of synthetic class II MHC peptides on alloimmune responses in vitro. Three peptides derived from a highly conserved region of the class II MHC alpha chains inhibited the rat mixed lymphocyte response (MLR) in a dose-dependent manner, with the human HLA-DQA1 peptide also inhibiting the human and mouse MLR. No effect was seen on mitogen-induced T-cell proliferation. HLA-DQA1 inhibited cytolytic T lymphocyte (CTL) generation in a dose-response fashion, with no reduction in preformed CTL killing, suggesting that the inhibitory effect is targeted at CD4(+) T-cell function. Cell-cycle analysis by flow cytometry showed that restimulation of primed T cells in the presence of HLA-DQA1 resulted in increased apoptosis, whereas unstimulated cells were not affected. These data demonstrate that synthetic peptides derived from highly conserved regions of the class II MHC alpha chain can alter CD4(+) T-lymphocyte alloimmune responses in vitro, and this effect is mediated by the induction of apoptosis in activated T cells.  (+info)

Clinical, immunological, and genetic heterogeneity of diabetes in an Italian population-based cohort of lean newly diagnosed patients aged 30-54 years. Piedmont Study Group for Diabetes Epidemiology. (3/153)

OBJECTIVE: In lean diabetic patients, the presentation of the disease does not allow one to easily distinguish between type 1 and type 2. Aims of this study were to describe clinical, immunological, and genetic features of lean newly diagnosed diabetic patients. RESEARCH DESIGN AND METHODS: A population-based cohort of 130 lean (BMI < 25 kg/m2) newly diagnosed patients, aged 30-54 years, was identified among residents of the province of Turin. Islet cell antibodies (ICAs), anti-GAD, fasting and glucagon-stimulated C-peptide values, and HLA DQA1-DQB1 susceptibility genotypes were assessed within 2 months of the diagnosis. RESULTS: A total of 45 (34.6%) and 29 (22.3%) patients were, respectively, ICA+ and anti-GAD+, with 15 (11.5%) having both antibodies. In 59 patients, ICAs and/or anti-GAD antibodies were detected, giving a high prevalence of autoimmunity (45.4%, 95% Cl 36.8-54.0); relative to patients without markers (n = 71), they were younger (40.8 +/- 7.5 vs. 45.0 +/- 6.5 years, P < 0.001) and showed lower values of fasting C-peptide (0.56 +/- 0.33 vs. 0.79 +/- 0.41 nmol/l, P < 0.001) and stimulated C-peptide (1.03 +/- 0.56 vs. 1.42 +/- 0.69 nmol/l, P < 0.001). The lowest stimulated C-peptide values were found in patients with both ICA and anti-GAD antibodies. Frequencies of adult-onset type 1 and type 2 diabetes were, respectively, 49.2 and 50.8%. Clinical and genetic features were not useful in the classification of patients. CONCLUSIONS: Almost 50% of lean young and middle-aged patients were ICA+ and/or anti-GAD+, suggesting a high prevalence of a slowly evolving form of type 1 diabetes. The evaluation at diagnosis of both beta-cell secretory capacity and markers of autoimmunity is recommended to provide a pathogenetic classification of the disease.  (+info)

HLA class II homozygosity confers susceptibility to common variable immunodeficiency (CVID). (4/153)

Most cases of CVID occur sporadically, but familial cases do also occur and 15% of the patients with the disease have first degree relatives with IgA deficiency (IgAD). Our purpose was to study CVID association with HLA class II alleles and to ascertain whether this disease shares a common genetic background with IgAD in our population. Patients with CVID (n = 42), were typed using gene amplification and sequence-specific oligonucleotide probing for HLA-DRB1, DRB3, DQA1 and DQB1 loci and their typing compared with that of 96 IgAD and 334 healthy controls. We observed a positive association between non-Asp residues at position 57 of the HLA-DQbeta chain and CVID, although much weaker than in IgAD. Further, we found an association between CVID and homozygosity for genes encoding HLA class II molecules, especially HLA-DQ, not seen in IgAD. The data support the hypothesis that a restricted diversity of HLA class II molecules may contribute to susceptibility to CVID.  (+info)

Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. (5/153)

OBJECTIVE: To better understand genetic contributions to autoimmunity, immunogenetic markers were studied in two racially discrete and geographically isolated populations of patients with idiopathic inflammatory myopathy (IIM). METHODS: Clinical characteristics, as well as clinical and autoantibody subsets, were defined in 151 American white patients and 50 Korean patients with IIM. HLA-DRB1 and DQA1 genotyping was performed on patients and racially matched controls by standard molecular techniques. Gm allotypes and phenotypes were determined by the hemagglutination-inhibition method. RESULTS: HLA-DRB1*0301, the linked allele DQA1*0501, and DRB1 alleles sharing the first hypervariable region motif 9EYSTS13 were major genetic risk factors for the development of myositis in whites (corrected P [Pcorr] < 0.0004, odds ratio [OR] 11.2, 4.5, and 3.1, respectively, for each factor versus controls). Although both the white and Korean patients had a similar distribution of clinical characteristics, autoantibody profiles, and clinical groups, no HLA-DRB1 nor DQA1 allele or motif was found to be a risk factor for IIM in the Korean patients. However, DRB1*14 was a protective factor in Korean patients without myositis-specific autoantibodies (Pcorr = 0.004, OR 0.046). In addition, although no Gm phenotype or allotype was identified as a risk factor in whites, Gm 21 was a protective factor for the development of IIM in Koreans (Pcorr = 0.024, OR 0.3). CONCLUSION: Although myositis patients in the US and Korea share similar clinical and serologic features, the immune response genes predisposing to and protecting from myositis in each of these ethnic groups differ at two chromosomal loci. These data suggest that multiple genetic loci should be studied to identify risk and protective factors for some autoimmune diseases in various ethnic populations.  (+info)

HLA-DQA1, -DQB1 polymorphism distribution in Chinese women with pregnancy induced hypertension in Shanghai area. (6/153)

OBJECTIVE: To explore the association of human leukocyte antigen (HLA) with pregnancy induced hypertension (PIH). METHODS: We oligotyped HLA-DQA1, -DQB1 locus of 30 Chinese PIH families and 14 control families in Shanghai area by polymerase chain reaction-sequence specific oligonucleotide (PCR-SSO) hybridization method (probes labeled by nonradioactive technique). RESULTS: Compared with the control group, the allelic frequency of HLA-DQB1 * 0502 was significantly higher in PIH couples, and the sharing of HLA-DQA1 increased in PIH couples as well. No difference was found in HLA-DQA1 allelic frequencies or HLA-DQB1 sharing between the two groups. Analysis of neither HLA-DQA1 nor HLA-DQB1 allelic frequencies in PIH patients and PIH mother-and-fetuses showed positive result. CONCLUSION: HLA-DQB1 * 0502 may be a marker of susceptibility to PIH. DQB1 * 0502 itself or some gene(s) located in HLA class II region and in linkage disequilibrium with 0502 affect maternal T cell immunity during pregnancy. The increase of compatibility in HLA-D region causes the production of blocking antibody to decrease.  (+info)

No support for HLA-DQ encoded susceptibility in rheumatoid arthritis. (7/153)

OBJECTIVE: To test predictions based on data from immunogenetic and peptide-binding studies of collagen-induced arthritis in mice, in which it has been suggested that susceptibility to rheumatoid arthritis (RA) might be determined by the interaction between susceptibility alleles at the HLA-DQ locus and protective alleles at the HLA-DRB1 locus (including susceptibility effects for HLA-DQ7 and DQ8). METHODS: Predictions based on these models were tested in 166 healthy controls and 167 patients with RA, all of whom were typed for HLA-DRB1 and HLA-DQ alleles. RESULTS: In this population, HLA-DQ7 did not encode an increased risk for RA. This lack of susceptibility effect of HLA-DQ7 could not be attributed to competing HLA-DQ susceptibility alleles, protective HLA-DRB1 alleles, or the absence of DQA1*0301. CONCLUSION: These observations do not support the DR/DQ hypothesis in its present form.  (+info)

Heterophile anti-mouse immunoglobulin antibodies may interfere with cytokine measurements in patients with HLA alleles protective for type 1A diabetes. (8/153)

Wilson and coworkers (Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, Porcelli S, Schatz DA, Atkinson MA, Balk SP, Strominger JL, Hafler DA: Extreme Th1 bias of invariant V alpha24J alpha Q T-cells in type 1 diabetes. Nature 391:177-181, 1998) have recently reported raised serum levels of interleukin-4 (IL-4) in anti-islet autoantibody-positive first-degree relatives of patients with type 1A diabetes who did not progress to diabetes. Protection from diabetes has been noted for several human lymphocyte antigen (HLA) alleles, such as HLA DR2-DQA1*0102-DQB1*0602. We, therefore, wanted to determine whether this cytokine phenotype was associated with HLA genes protective for type 1A diabetes. We used a two-site fluoroimmunoassay with the same monoclonal antibodies as those reported by Wilson et al. Using this assay, we have found evidence for human heterophile antibodies mimicking serum IL-4: all serum IL-4 reactivity was lost if mouse serum or mouse immunoglobulin were added to the assay; serum IL-4 activity was bound and then eluted by protein A/G chromatography; and levels of anti-mouse antibodies correlated with apparent serum IL-4. This pseudo-IL-4 activity was found in a subset of control subjects, patients with type 1A diabetes, and their relatives and was primarily associated with specific HLA alleles protective for type 1A diabetes (e.g., DQB1*0602). After adjustment for HLA, positive levels of heterophile antibodies were not associated with protection from diabetes. The confounding effect of protective HLA alleles associated with heterophile antibodies could explain the previously reported association between raised serum IL-4 and protection from type 1A diabetes. The mechanism by which specific DQ alleles protect from diabetes and are associated with increased heterophile antibodies is currently unknown.  (+info)

HLA-DQ antigens are a type of human leukocyte antigen (HLA) that are found on the surface of cells in our body. They are a part of the major histocompatibility complex (MHC) class II molecules, which play a crucial role in the immune system by presenting pieces of proteins from outside the cell to CD4+ T cells, also known as helper T cells. This presentation process is essential for initiating an appropriate immune response against potentially harmful pathogens such as bacteria and viruses.

HLA-DQ antigens are encoded by genes located on chromosome 6p21.3 in the HLA region. Each individual inherits a pair of HLA-DQ genes, one from each parent, which can result in various combinations of HLA-DQ alleles. These genetic variations contribute to the diversity of immune responses among different individuals.

HLA-DQ antigens consist of two noncovalently associated polypeptide chains: an alpha (DQA) chain and a beta (DQB) chain. There are several isotypes of HLA-DQ antigens, including DQ1, DQ2, DQ3, DQ4, DQ5, DQ6, DQ7, DQ8, and DQ9, which are determined by the specific combination of DQA and DQB alleles.

Certain HLA-DQ genotypes have been associated with an increased risk of developing certain autoimmune diseases, such as celiac disease (DQ2 and DQ8), type 1 diabetes (DQ2, DQ8), and rheumatoid arthritis (DQ4). Understanding the role of HLA-DQ antigens in these conditions can provide valuable insights into disease pathogenesis and potential therapeutic targets.

Celiac disease is a genetic autoimmune disorder in which the consumption of gluten, a protein found in wheat, barley, and rye, leads to damage in the small intestine. In people with celiac disease, their immune system reacts to gluten by attacking the lining of the small intestine, leading to inflammation and destruction of the villi - finger-like projections that help absorb nutrients from food.

This damage can result in various symptoms such as diarrhea, bloating, fatigue, anemia, and malnutrition. Over time, if left untreated, celiac disease can lead to serious health complications, including osteoporosis, infertility, neurological disorders, and even certain types of cancer.

The only treatment for celiac disease is a strict gluten-free diet, which involves avoiding all foods, beverages, and products that contain gluten. With proper management, individuals with celiac disease can lead healthy lives and prevent further intestinal damage and related health complications.

HLA (Human Leukocyte Antigen) antigens are a group of proteins found on the surface of cells in our body. They play a crucial role in the immune system's ability to differentiate between "self" and "non-self." HLA antigens are encoded by a group of genes located on chromosome 6, known as the major histocompatibility complex (MHC).

There are three types of HLA antigens: HLA class I, HLA class II, and HLA class III. HLA class I antigens are found on the surface of almost all cells in the body and help the immune system recognize and destroy virus-infected or cancerous cells. They consist of three components: HLA-A, HLA-B, and HLA-C.

HLA class II antigens are primarily found on the surface of immune cells, such as macrophages, B cells, and dendritic cells. They assist in the presentation of foreign particles (like bacteria and viruses) to CD4+ T cells, which then activate other parts of the immune system. HLA class II antigens include HLA-DP, HLA-DQ, and HLA-DR.

HLA class III antigens consist of various molecules involved in immune responses, such as cytokines and complement components. They are not directly related to antigen presentation.

The genetic diversity of HLA antigens is extensive, with thousands of variations or alleles. This diversity allows for a better ability to recognize and respond to a wide range of pathogens. However, this variation can also lead to compatibility issues in organ transplantation, as the recipient's immune system may recognize the donor's HLA antigens as foreign and attack the transplanted organ.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

Polymerase Chain Reaction (PCR) is a laboratory technique used to amplify specific regions of DNA. It enables the production of thousands to millions of copies of a particular DNA sequence in a rapid and efficient manner, making it an essential tool in various fields such as molecular biology, medical diagnostics, forensic science, and research.

The PCR process involves repeated cycles of heating and cooling to separate the DNA strands, allow primers (short sequences of single-stranded DNA) to attach to the target regions, and extend these primers using an enzyme called Taq polymerase, resulting in the exponential amplification of the desired DNA segment.

In a medical context, PCR is often used for detecting and quantifying specific pathogens (viruses, bacteria, fungi, or parasites) in clinical samples, identifying genetic mutations or polymorphisms associated with diseases, monitoring disease progression, and evaluating treatment effectiveness.

A base sequence in the context of molecular biology refers to the specific order of nucleotides in a DNA or RNA molecule. In DNA, these nucleotides are adenine (A), guanine (G), cytosine (C), and thymine (T). In RNA, uracil (U) takes the place of thymine. The base sequence contains genetic information that is transcribed into RNA and ultimately translated into proteins. It is the exact order of these bases that determines the genetic code and thus the function of the DNA or RNA molecule.

Macromolecular substances, also known as macromolecules, are large, complex molecules made up of repeating subunits called monomers. These substances are formed through polymerization, a process in which many small molecules combine to form a larger one. Macromolecular substances can be naturally occurring, such as proteins, DNA, and carbohydrates, or synthetic, such as plastics and synthetic fibers.

In the context of medicine, macromolecular substances are often used in the development of drugs and medical devices. For example, some drugs are designed to bind to specific macromolecules in the body, such as proteins or DNA, in order to alter their function and produce a therapeutic effect. Additionally, macromolecular substances may be used in the creation of medical implants, such as artificial joints and heart valves, due to their strength and durability.

It is important for healthcare professionals to have an understanding of macromolecular substances and how they function in the body, as this knowledge can inform the development and use of medical treatments.

HLA-DR antigens are a type of human leukocyte antigen (HLA) class II molecule that plays a crucial role in the immune system. They are found on the surface of antigen-presenting cells, such as dendritic cells, macrophages, and B lymphocytes. HLA-DR molecules present peptide antigens to CD4+ T cells, also known as helper T cells, thereby initiating an immune response.

HLA-DR antigens are highly polymorphic, meaning that there are many different variants of these molecules in the human population. This diversity allows for a wide range of potential peptide antigens to be presented and recognized by the immune system. HLA-DR antigens are encoded by genes located on chromosome 6 in the major histocompatibility complex (MHC) region.

In transplantation, HLA-DR compatibility between donor and recipient is an important factor in determining the success of the transplant. Incompatibility can lead to a heightened immune response against the transplanted organ or tissue, resulting in rejection. Additionally, certain HLA-DR types have been associated with increased susceptibility to autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

Alpha 1-antitrypsin (AAT, or α1-antiproteinase, A1AP) is a protein that is primarily produced by the liver and released into the bloodstream. It belongs to a group of proteins called serine protease inhibitors, which help regulate inflammation and protect tissues from damage caused by enzymes involved in the immune response.

Alpha 1-antitrypsin is particularly important for protecting the lungs from damage caused by neutrophil elastase, an enzyme released by white blood cells called neutrophils during inflammation. In the lungs, AAT binds to and inhibits neutrophil elastase, preventing it from degrading the extracellular matrix and damaging lung tissue.

Deficiency in alpha 1-antitrypsin can lead to chronic obstructive pulmonary disease (COPD) and liver disease. The most common cause of AAT deficiency is a genetic mutation that results in abnormal folding and accumulation of the protein within liver cells, leading to reduced levels of functional AAT in the bloodstream. This condition is called alpha 1-antitrypsin deficiency (AATD) and can be inherited in an autosomal codominant manner. Individuals with severe AATD may require augmentation therapy with intravenous infusions of purified human AAT to help prevent lung damage.

Immunoglobulin alpha-chains (IgA) are a type of immunoglobulin or antibody that plays a crucial role in the immune system. They are composed of two heavy chains, known as alpha-chains, and two light chains. IgA is primarily found in secretions such as tears, saliva, breast milk, and respiratory and intestinal mucus, where they provide protection against pathogens that enter the body through these surfaces.

IgA can exist in two forms: a monomeric form, which consists of a single IgA molecule, and a polymeric form, which consists of several IgA molecules joined together by a J chain. The polymeric form is more common in secretions, where it provides an effective barrier against pathogens.

IgA functions by binding to antigens on the surface of pathogens, preventing them from attaching to and infecting host cells. It can also neutralize toxins produced by some bacteria and viruses. Additionally, IgA can activate the complement system, a group of proteins that work together to destroy pathogens, and initiate an immune response by recruiting other immune cells to the site of infection.

Deficiencies in IgA are relatively common and usually do not cause any significant health problems. However, in some cases, people with IgA deficiency may develop recurrent infections or allergies.

Adrenergic receptors are a type of G protein-coupled receptor that bind and respond to catecholamines, such as epinephrine (adrenaline) and norepinephrine (noradrenaline). Alpha adrenergic receptors (α-ARs) are a subtype of adrenergic receptors that are classified into two main categories: α1-ARs and α2-ARs.

The activation of α1-ARs leads to the activation of phospholipase C, which results in an increase in intracellular calcium levels and the activation of various signaling pathways that mediate diverse physiological responses such as vasoconstriction, smooth muscle contraction, and cell proliferation.

On the other hand, α2-ARs are primarily located on presynaptic nerve terminals where they function to inhibit the release of neurotransmitters, including norepinephrine. The activation of α2-ARs also leads to the inhibition of adenylyl cyclase and a decrease in intracellular cAMP levels, which can mediate various physiological responses such as sedation, analgesia, and hypotension.

Overall, α-ARs play important roles in regulating various physiological functions, including cardiovascular function, mood, and cognition, and are also involved in the pathophysiology of several diseases, such as hypertension, heart failure, and neurodegenerative disorders.

A peptide fragment is a short chain of amino acids that is derived from a larger peptide or protein through various biological or chemical processes. These fragments can result from the natural breakdown of proteins in the body during regular physiological processes, such as digestion, or they can be produced experimentally in a laboratory setting for research or therapeutic purposes.

Peptide fragments are often used in research to map the structure and function of larger peptides and proteins, as well as to study their interactions with other molecules. In some cases, peptide fragments may also have biological activity of their own and can be developed into drugs or diagnostic tools. For example, certain peptide fragments derived from hormones or neurotransmitters may bind to receptors in the body and mimic or block the effects of the full-length molecule.

Hypoxia-Inducible Factor 1 (HIF-1) is a transcription factor that plays a crucial role in the body's response to low oxygen levels, also known as hypoxia. HIF-1 is a heterodimeric protein composed of two subunits: an alpha subunit (HIF-1α) and a beta subunit (HIF-1β).

The alpha subunit, HIF-1α, is the regulatory subunit that is subject to oxygen-dependent degradation. Under normal oxygen conditions (normoxia), HIF-1α is constantly produced in the cell but is rapidly degraded by proteasomes due to hydroxylation of specific proline residues by prolyl hydroxylase domain-containing proteins (PHDs). This hydroxylation reaction requires oxygen as a substrate, and under hypoxic conditions, the activity of PHDs is inhibited, leading to the stabilization and accumulation of HIF-1α.

Once stabilized, HIF-1α translocates to the nucleus, where it heterodimerizes with HIF-1β and binds to hypoxia-responsive elements (HREs) in the promoter regions of target genes. This binding results in the activation of gene transcription programs that promote cellular adaptation to low oxygen levels. These adaptive responses include increased erythropoiesis, angiogenesis, glucose metabolism, and pH regulation, among others.

Therefore, HIF-1α is a critical regulator of the body's response to hypoxia, and its dysregulation has been implicated in various pathological conditions, including cancer, cardiovascular disease, and neurodegenerative disorders.

Protein binding, in the context of medical and biological sciences, refers to the interaction between a protein and another molecule (known as the ligand) that results in a stable complex. This process is often reversible and can be influenced by various factors such as pH, temperature, and concentration of the involved molecules.

In clinical chemistry, protein binding is particularly important when it comes to drugs, as many of them bind to proteins (especially albumin) in the bloodstream. The degree of protein binding can affect a drug's distribution, metabolism, and excretion, which in turn influence its therapeutic effectiveness and potential side effects.

Protein-bound drugs may be less available for interaction with their target tissues, as only the unbound or "free" fraction of the drug is active. Therefore, understanding protein binding can help optimize dosing regimens and minimize adverse reactions.

Immunoglobulin heavy chains are proteins that make up the framework of antibodies, which are Y-shaped immune proteins. These heavy chains, along with light chains, form the antigen-binding sites of an antibody, which recognize and bind to specific foreign substances (antigens) in order to neutralize or remove them from the body.

The heavy chain is composed of a variable region, which contains the antigen-binding site, and constant regions that determine the class and function of the antibody. There are five classes of immunoglobulins (IgA, IgD, IgE, IgG, and IgM) that differ in their heavy chain constant regions and therefore have different functions in the immune response.

Immunoglobulin heavy chains are synthesized by B cells, a type of white blood cell involved in the adaptive immune response. The genetic rearrangement of immunoglobulin heavy chain genes during B cell development results in the production of a vast array of different antibodies with unique antigen-binding sites, allowing for the recognition and elimination of a wide variety of pathogens.

Histocompatibility antigens Class II are a group of cell surface proteins that play a crucial role in the immune system's response to foreign substances. They are expressed on the surface of various cells, including immune cells such as B lymphocytes, macrophages, dendritic cells, and activated T lymphocytes.

Class II histocompatibility antigens are encoded by the major histocompatibility complex (MHC) class II genes, which are located on chromosome 6 in humans. These antigens are composed of two non-covalently associated polypeptide chains, an alpha (α) and a beta (β) chain, which form a heterodimer. There are three main types of Class II histocompatibility antigens, known as HLA-DP, HLA-DQ, and HLA-DR.

Class II histocompatibility antigens present peptide antigens to CD4+ T helper cells, which then activate other immune cells, such as B cells and macrophages, to mount an immune response against the presented antigen. Because of their role in initiating an immune response, Class II histocompatibility antigens are important in transplantation medicine, where mismatches between donor and recipient can lead to rejection of the transplanted organ or tissue.

In the context of medicine and pharmacology, "kinetics" refers to the study of how a drug moves throughout the body, including its absorption, distribution, metabolism, and excretion (often abbreviated as ADME). This field is called "pharmacokinetics."

1. Absorption: This is the process of a drug moving from its site of administration into the bloodstream. Factors such as the route of administration (e.g., oral, intravenous, etc.), formulation, and individual physiological differences can affect absorption.

2. Distribution: Once a drug is in the bloodstream, it gets distributed throughout the body to various tissues and organs. This process is influenced by factors like blood flow, protein binding, and lipid solubility of the drug.

3. Metabolism: Drugs are often chemically modified in the body, typically in the liver, through processes known as metabolism. These changes can lead to the formation of active or inactive metabolites, which may then be further distributed, excreted, or undergo additional metabolic transformations.

4. Excretion: This is the process by which drugs and their metabolites are eliminated from the body, primarily through the kidneys (urine) and the liver (bile).

Understanding the kinetics of a drug is crucial for determining its optimal dosing regimen, potential interactions with other medications or foods, and any necessary adjustments for special populations like pediatric or geriatric patients, or those with impaired renal or hepatic function.

In the context of medical and biological sciences, a "binding site" refers to a specific location on a protein, molecule, or cell where another molecule can attach or bind. This binding interaction can lead to various functional changes in the original protein or molecule. The other molecule that binds to the binding site is often referred to as a ligand, which can be a small molecule, ion, or even another protein.

The binding between a ligand and its target binding site can be specific and selective, meaning that only certain ligands can bind to particular binding sites with high affinity. This specificity plays a crucial role in various biological processes, such as signal transduction, enzyme catalysis, or drug action.

In the case of drug development, understanding the location and properties of binding sites on target proteins is essential for designing drugs that can selectively bind to these sites and modulate protein function. This knowledge can help create more effective and safer therapeutic options for various diseases.

HLA-DQ beta-chains are a type of human leukocyte antigen (HLA) molecule found on the surface of cells in the human body. The HLAs are a group of proteins that play an important role in the immune system by helping the body recognize and respond to foreign substances, such as viruses and bacteria.

The HLA-DQ beta-chains are part of the HLA-DQ complex, which is a heterodimer made up of two polypeptide chains: an alpha chain (HLA-DQ alpha) and a beta chain (HLA-DQ beta). These chains are encoded by genes located on chromosome 6 in the major histocompatibility complex (MHC) region.

The HLA-DQ complex is involved in presenting peptides to CD4+ T cells, which are a type of white blood cell that plays a central role in the immune response. The peptides presented by the HLA-DQ complex are derived from proteins that have been processed within the cell, and they are used to help the CD4+ T cells recognize and respond to infected or abnormal cells.

Variations in the genes that encode the HLA-DQ beta-chains can affect an individual's susceptibility to certain diseases, including autoimmune disorders and infectious diseases.

Recombinant proteins are artificially created proteins produced through the use of recombinant DNA technology. This process involves combining DNA molecules from different sources to create a new set of genes that encode for a specific protein. The resulting recombinant protein can then be expressed, purified, and used for various applications in research, medicine, and industry.

Recombinant proteins are widely used in biomedical research to study protein function, structure, and interactions. They are also used in the development of diagnostic tests, vaccines, and therapeutic drugs. For example, recombinant insulin is a common treatment for diabetes, while recombinant human growth hormone is used to treat growth disorders.

The production of recombinant proteins typically involves the use of host cells, such as bacteria, yeast, or mammalian cells, which are engineered to express the desired protein. The host cells are transformed with a plasmid vector containing the gene of interest, along with regulatory elements that control its expression. Once the host cells are cultured and the protein is expressed, it can be purified using various chromatography techniques.

Overall, recombinant proteins have revolutionized many areas of biology and medicine, enabling researchers to study and manipulate proteins in ways that were previously impossible.

Molecular cloning is a laboratory technique used to create multiple copies of a specific DNA sequence. This process involves several steps:

1. Isolation: The first step in molecular cloning is to isolate the DNA sequence of interest from the rest of the genomic DNA. This can be done using various methods such as PCR (polymerase chain reaction), restriction enzymes, or hybridization.
2. Vector construction: Once the DNA sequence of interest has been isolated, it must be inserted into a vector, which is a small circular DNA molecule that can replicate independently in a host cell. Common vectors used in molecular cloning include plasmids and phages.
3. Transformation: The constructed vector is then introduced into a host cell, usually a bacterial or yeast cell, through a process called transformation. This can be done using various methods such as electroporation or chemical transformation.
4. Selection: After transformation, the host cells are grown in selective media that allow only those cells containing the vector to grow. This ensures that the DNA sequence of interest has been successfully cloned into the vector.
5. Amplification: Once the host cells have been selected, they can be grown in large quantities to amplify the number of copies of the cloned DNA sequence.

Molecular cloning is a powerful tool in molecular biology and has numerous applications, including the production of recombinant proteins, gene therapy, functional analysis of genes, and genetic engineering.

1. Receptors: In the context of physiology and medicine, receptors are specialized proteins found on the surface of cells or inside cells that detect and respond to specific molecules, known as ligands. Receptors play a crucial role in signal transduction, enabling cells to communicate with each other and respond to changes in their environment.
2. Antigen: An antigen is any substance (usually a protein) that can be recognized by the immune system and stimulate an immune response. Antigens can be foreign substances such as bacteria, viruses, or pollen, or they can be components of our own cells, such as tumor antigens in cancer cells. Antigens are typically bound and presented to the immune system by specialized cells called antigen-presenting cells (APCs).
3. T-Cell: T-cells, also known as T lymphocytes, are a type of white blood cell that plays a central role in cell-mediated immunity. T-cells are produced in the bone marrow and mature in the thymus gland. There are two main types of T-cells: CD4+ helper T-cells and CD8+ cytotoxic T-cells. Helper T-cells assist other immune cells, such as B-cells and macrophages, in mounting an immune response, while cytotoxic T-cells directly kill infected or cancerous cells.
4. Alpha-Beta: Alpha-beta is a type of T-cell receptor (TCR) that is found on the surface of most mature T-cells. The alpha-beta TCR is composed of two polypeptide chains, an alpha chain and a beta chain, that are held together by disulfide bonds. The alpha-beta TCR recognizes and binds to specific antigens presented in the context of major histocompatibility complex (MHC) molecules on the surface of APCs. This interaction is critical for initiating an immune response against infected or cancerous cells.

Hemoglobin A is the most common form of hemoglobin, which is the oxygen-carrying protein in red blood cells. Hemoglobin A is a tetramer composed of two alpha and two beta globin chains, each containing a heme group that binds to oxygen. It is typically measured in laboratory tests to assess for various medical conditions such as anemia or diabetes. In the context of diabetes, the measurement of hemoglobin A1c (a form of hemoglobin A that is glycated or bound to glucose) is used to monitor long-term blood sugar control.

HLA-D antigens, also known as HLA class II antigens, are a group of proteins found on the surface of cells that play an important role in the immune system. "HLA" stands for Human Leukocyte Antigen, which is a part of the major histocompatibility complex (MHC) in humans.

HLA-D antigens are primarily expressed by immune cells such as B lymphocytes, macrophages, and dendritic cells, but they can also be found on other cell types under certain conditions. These antigens help the immune system distinguish between "self" and "non-self" by presenting pieces of proteins (peptides) from both inside and outside the cell to T lymphocytes, a type of white blood cell that is crucial for mounting an immune response.

HLA-D antigens are divided into three subtypes: HLA-DP, HLA-DQ, and HLA-DR. Each subtype has a specific function in presenting peptides to T lymphocytes. The genes that encode HLA-D antigens are highly polymorphic, meaning there are many different variations of these genes in the population. This genetic diversity allows for a better match between an individual's immune system and the wide variety of pathogens they may encounter.

Abnormalities in HLA-D antigens have been associated with several autoimmune diseases, such as rheumatoid arthritis, type 1 diabetes, and multiple sclerosis. Additionally, certain variations in HLA-D genes can influence the severity of infectious diseases, such as HIV/AIDS and hepatitis C.

Interleukin-2 (IL-2) receptors are a type of cell surface receptor that bind to and interact with the cytokine interleukin-2. IL-2 is a protein that plays an important role in the immune system, particularly in the activation and proliferation of T cells, a type of white blood cell that helps protect the body from infection and disease.

IL-2 receptors are composed of three subunits: alpha (CD25), beta (CD122), and gamma (CD132). These subunits can combine to form different types of IL-2 receptors, each with different functions. The high-affinity IL-2 receptor is made up of all three subunits and is found on the surface of activated T cells. This type of receptor has a strong binding affinity for IL-2 and plays a crucial role in T cell activation and proliferation.

The intermediate-affinity IL-2 receptor, which consists of the beta and gamma subunits, is found on the surface of resting T cells and natural killer (NK) cells. This type of receptor has a lower binding affinity for IL-2 and plays a role in activating and proliferating these cells.

IL-2 receptors are important targets for immunotherapy, as they play a key role in the regulation of the immune response. Drugs that target IL-2 receptors, such as aldesleukin (Proleukin), have been used to treat certain types of cancer and autoimmune diseases.

Major Histocompatibility Complex (MHC) Class II genes are a group of genes that encode cell surface proteins responsible for presenting peptide antigens to CD4+ T cells, which are crucial in the adaptive immune response. These proteins are expressed mainly on professional antigen-presenting cells such as dendritic cells, macrophages, and B cells. MHC Class II molecules present extracellular antigens derived from bacteria, viruses, and other pathogens, facilitating the activation of appropriate immune responses to eliminate the threat. The genes responsible for these proteins are found within the MHC locus on chromosome 6 in humans (chromosome 17 in mice).

"HLA-DQ alpha-Chains" by people in this website by year, and whether "HLA-DQ alpha-Chains" was a major or minor topic of these ... HLA-DQ alpha-Chains*HLA-DQ alpha-Chains. *HLA DQ alpha Chains ... HLA-DQ alpha-Chains [D23.050.301.500.400.400.430.500]. *HLA ... "HLA-DQ alpha-Chains" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "HLA-DQ alpha-Chains" by people in Profiles. ...
HLA-DQ Antigens / genetics * HLA-DQ alpha-Chains * HLA-DQ beta-Chains ... HLA class II polymorphism in cystic fibrosis. A possible modifier of pulmonary phenotype Am J Respir Crit Care Med. 1999 May; ... As human leukocyte antigen (HLA) class II polymorphism has been associated with a number of diseases including autoimmune and ... inflammatory diseases, asthma, and allergy, we investigated the possibility that HLA polymorphism contributes to CF-associated ...
... the β subunit more so than the alpha chain. The variants are encoded by the HLA DQ genes and are the result of single ... The DQ loci are in close genetic linkage to HLA-DR, and less closely linked to HLA-DP, HLA-A, HLA-B and HLA-C. Different ... Both α-chain and β-chain vary greatly. A person often produces two α-chain and two β-chain variants and thus 4 isoforms of DQ. ... Serological studies of DQ recognized that antibodies to DQ bind primarily to the β-chain. The currently used serotypes are HLA- ...
View Mouse Monoclonal anti-HLA DRB1 Antibody (LN-3 + HLA-DRB/1067) (NBP2-45316). Validated Applications: WB, Flow, ICC/IF, IHC ... It does not cross react with HLA-DP and HLA-DQ. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36kDa alpha ... This monoclonal antibody reacts with the beta-chain of HLA-DRB1 antigen, a member of MHC class II molecules. ... Home » HLA DRB1 » HLA DRB1 Antibodies » HLA DRB1 Antibody (LN-3 + HLA-DRB/1067) ...
... the DQ molecules differ markedly in function, even when present with the same DQ alpha subunit. For this reason they are best ... While the DQ3 molecules are structurally similar in beta chain, ... antigens recognized as HLA-DQ along with HLA-DQ1 and HLA-DQ2. ... DQB1*0301 the DQ7 gene, is detailed on HLA-DQ7 DQB1*0302 the DQ8 gene, is detailed on HLA-DQ8 DQB1*0303 the DQ9 gene, is ... Within molecular and cell biology, HLA-DQ3 (DQ3) is a broad serotype category with split antigens HLA-DQ7, DQ8, and DQ9. ...
The HLA-DQA1 gene provides instructions for making a protein that plays a critical role in the immune system. Learn about this ... HLA class II histocompatibility antigen, DQ alpha 1 chain. *HLA class II histocompatibility antigen, DQ alpha 1 chain precursor ... 01 or HLA-DQA1*05:05 bound to the protein produced from HLA-DQB1 gene variants known as HLA-DQB1*02:01 or HLA-DQB1*02:02. The ... is most increased by two HLA haplotypes involving variations of the HLA-DQA1 and HLA-DQB1 genes and another HLA gene called HLA ...
PDB Compounds: (D:) hla class II histocompatibility antigen, dr alpha chain. SCOPe Domain Sequences for d1zgld1:. Sequence; ... probably orthologous to the human HLA-DQ group. *. Domain d1zgld1: 1zgl D:83-179 [125035]. Other proteins in same PDB: d1zgla2 ... d1zgld1 b.1.1.2 (D:83-179) Class II MHC alpha chain, C-terminal domain {Mouse (Mus musculus), I-A group [TaxId: 10090]} ... Protein Class II MHC alpha chain, C-terminal domain [88618] (7 species). ...
HLA-DQ alpha-Chains/genetics, Humans, Immunosuppressive Agents/therapeutic use, Infliximab/therapeutic use, Interferon beta-1a/ ... We found that the HLA-DQA1*05 allele was associated with an increased rate of immunogenicity. Moreover, our results suggest a ... We found that the HLA-DQA1*05 allele was associated with an increased rate of immunogenicity. Moreover, our results suggest a ... We found that the HLA-DQA1*05 allele was associated with an increased rate of immunogenicity. Moreover, our results suggest a ...
The alpha chain is encoded by one of the HLA-D genes, while the beta chain is encoded by one of the HLA-DP, HLA-DQ, or HLA-DR ... The beta1 domain is involved in binding to the alpha chain, while the beta2 domain forms the roof of the peptide-binding groove ... The interactions between the alpha and beta chains are critical for the stability of the MHC class II molecule. The alpha1 and ... The MHC class II molecule is stabilized by disulfide bonds between the alpha and beta chains, as well as interactions with the ...
used PCR to enzymatically amplify a specific segment of beta-globin or HLA-DQ alpha gene in human genomic DNA [21]. ... Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology is applied to HLA-DR, -DQ and -DW ... Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele specific oligonucleotide probes Nature 1986; ... Polymerase chain reaction-sequencing-based typing (PCR-SBT) is used for HLA-B51 alleles. Evaluation of intraocular cytokines ...
Anti-HLA-DR Monoclonal (LN3), eBioscience™, Catalog # 62-9956-42. Tested in Flow Cytometry (Flow) applications. This antibody ... HLA class II histocompatibility antigen, DR alpha chain; HLA class II histocompatibility antigen, DR beta 3 chain; HLA class II ... Three loci, DR, DQ and DP, encode the major expressed products of the human class II region. The human MHC class II molecules ... HLA: HLA-DRA, HLA-DRB1, HLA-DRB5, HLA-DPA1, HLA-DPB1, HLA-DMA, HLA-DQA1, HLA-DQA2, HLA-DQB1, CD74. Interferon: IFIT1, IFIT2, ...
Using genetic data of parental lifespan, the authors identify associations at HLA-DQA/DRB1 and LPA and find that genetic ... HLA-DQA1/DRB1 and LPA). We also validate previous suggestions that APOE, CHRNA3/5, CDKN2A/B, SH2B3 and FOXO3A influence ... HLA-DQ alpha-Chains, HLA-DRB1 Chains, Humans, Insulin Resistance, Life Style, Lipoprotein(a), Lipoproteins, HDL, Longevity, ... Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity. ...
... alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of ... They are extremely polymorphic families of glycopeptides, each consisting of two chains, ... Human Class II Antigens -- See HLA-D Antigens Human immune-response or Class II antigens found mainly, but not exclusively, on ... In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in ...
... alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of ... They are extremely polymorphic families of glycopeptides, each consisting of two chains, ... Human Class II Antigens -- See HLA-D Antigens Human immune-response or Class II antigens found mainly, but not exclusively, on ... In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in ...
HLA) System - Etiology, pathophysiology, symptoms, signs, diagnosis & prognosis from the MSD Manuals - Medical Professional ... Both polypeptide chains are encoded by genes in the HLA-DP, -DQ, or -DR region of chromosome 6. T cells reactive to class II ... Class II MHC molecules consist of 2 polypeptide (alpha [α] and beta [β]) chains; each chain has a peptide-binding domain, an Ig ... The heavy chain of the class I molecule is encoded by genes at HLA-A, HLA-B, and HLA-C loci. T cells that express CD8 molecules ...
Clone NP-7 expressed V beta 6.5 but rearranged two in-frame TCR alpha chain, both using the V alpha 22.1 segment. Fine epitope ... We have shown that thyroid epithelial cells (TEC), the only cells that produce TPO, express HLA class II molecules in Graves ... Three clones (37, 72, and 73) expressed identical TCR beta and alpha chains rearranging V beta 1.1 and V alpha 15.1, and were ... mapping using nested peptides showed that clones using identical TCR beta chains, identical V alpha, but a different J alpha ...
HLA DQ-alpha. A polymorphic gene in the Human Leukocyte Antigen (HLA) region of chromosome 6 that has been well studied and ... A tetrameric protein composed of two identical light chains and two identical heavy chains. Specific proteins produced by ... a whole or partial chain of DNA) not originally (biologically) present in that chain.. Recombination. The reversal of coupling ... Chain of Custody. A record of individuals who have had physical possession of the evidence and the process used to maintain and ...
HLA) class II molecules HLA-DP, HLA-DQ and HLA-DR heterodimeric cell surface glycoproteins comprised of an α (heavy) chain and ... HLA-B27 (HLA Class I Histocompatibility Antigen, B-27 alpha Chain): * HLA-B27 Antibodies ... HLA-DP/DQ/DR - MHC Class II HLA-DP/DQ/DR: * Show all MHC Class II HLA-DP/DQ/DR products ... HLA-E (HLA Class I Histocompatibility Antigen, alpha Chain E): * HLA-E Antibodies ...
Find high quality MHC Class II HLA-DP/DQ/DR tools for research. Antibodies, ELISA kits, proteins, reagents. Order quickly and ... MHC Class I RT1.Aa alpha-Chain * MHC Class I H-2Kd ... MHC Class II HLA-DP/DQ/DR Produits. (MHC Class II HLA-DP/DQ/DR ... Dernières publications sur nos produits MHC Class II HLA-DP/DQ/DR. Kissner, Ruthel, Alam, Ulrich, Fernandez, Saikh: "Activation ... 58 and YD1/63.HLK directed against human HLA class II antigens." dans: Immunobiology, Vol. 171, Issue 1-2, pp. 77-92, (1986) ( ...
HLA-DQ alpha-Chains. * Humans. * Immunoglobulin E. * Male. * Polymorphism, Single Nucleotide. * Transcription Factors ...
Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain. Benson, M.D., Liepnieks, J., Uemichi, T., Wheeler ... Major histocompatibility complex (MHC) class II alleles (HLA-DR and DQ) were determined by restriction fragment length ... Thus, a restriction fragment length polymorphism in the TNF-alpha gene correlates with the reduced levels of TNF-alpha produced ... Since a dysregulated synthesis of tumor necrosis factor alpha (TNF-alpha) may be involved in the pathogenesis of autoimmune ...
3 HIX0027959 6p21.32 HLA-DQA1 HLA class II histocompatibility antigen, DQ(5) alpha chain precursor (DC-1 alpha chain). ... hap2 HLA-F HLA class I histocompatibility antigen, alpha chain F; HLA F antigen; Leukocyte antigen F; CDA12; Precursor; ... 8 HIX0005683 6p21.32 HLA-G HLA class I histocompatibility antigen, alpha chain G precursor (HLA G antigen). HIF0000002 Major ... hap6 HLA-A HLA class I histocompatibility antigen, A-26 alpha chain precursor (MHC class I antigen A*26). HIF0000002 Major ...
HLA-DR Antigens. A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs ... from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.. ... INTERLEUKIN-10 RECEPTOR ALPHA CHAIN) and two beta chains ( ... Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is ... Receptor, Interferon alpha-beta. A ubiquitously expressed heterodimeric receptor that is specific for both INTERFERON-ALPHA and ...
The human Class II MHC antigens are HLA-DR, DP AND DQ, where DR is of primary interest. ... alpha.-subunit of the HLA-DR gene of the host cell. In this way cells which have the Class II MHC antigen or may have the ... The polymerase chain reaction may be used with advantage in detecting the presence of homologous recombination. Primers may be ... CD8 bearing .alpha..beta.+ T-cells did not appear in greater numbers after such treatment, although .gamma..delta. bearing T ...
We found that heterogeneity due to post synthetic modification of beta and alpha chains of DR and DQ can be avoided by labeling ... A mixture of ampholytes pH range 3.5-10:5-7 of 1:4 run for 3000 V/h gave the best resolution of beta and alpha chains. With ... this technique we could clearly reveal differences in the DR beta-2 chains of those DR2 haplotypes, Dw2, Dw12 and LDtb24. The ... Two-dimensional gel electrophoresis of material immunoprecipitated from radiolabeled cells by anti-HLA class II monoclonal ...
HLA Class II reactive sera from kidney allograft recipients: detection of antibodies specific for epitops of DQ and DP alpha/ ... detection of antibodies specific for epitops of DQ and DP alpha/beta chains (Abstract/Poster in atti di convegno) (http://www. ... RARA ASSOCIAZIONE HLA DR-DQ (Contributo in atti di convegno) (Prodotto della ricerca) ... RARA ASSOCIAZIONE HLA DR-DQ (Contributo in atti di convegno) (Prodotto della ricerca) ...
HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD &alpha; (heavy) chain and a 27 kD β (light) chain ... It does not cross react with HLA-DP and HLA-DQ. Clone L243 binds a conformational epitope on HLA-DRa which depends on the ... HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD α (heavy) chain and a 27 kD β (light) chain. It is ... In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T ...
Crystallin A Chain N0000169036 alpha-Crystallin A Chain ... beta-1b N0000183454 HLA-DR beta-Chains N0000183520 HLA-DQ beta- ... alpha-Crystallin A Chain. One of the subunits of alpha-crystallins. Unlike ALPHA-CRYSTALLIN B CHAIN the expression of ALPHA- ... Chainbeta-Crystallin A Chaingamma-Crystallinsbeta-Crystallinsalpha-Crystallin A Chainalpha-Crystallinsalpha-Crystallin B Chain ... and beta-chains have reacted with cyanate, (ii) alpha(c) (2)beta(2), in which the alpha-amino groups of the alpha-chains have ...
Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. Diabetes 2014, 63, 237-247. [Google ... Lu, Y.; Fan, C.; Li, P.; Lu, Y.; Chang, X.; Qi, K. Short Chain Fatty Acids Prevent High-fat-diet-induced Obesity in Mice by ... Schalk, K.; Lang, C.; Wieser, H.; Koehler, P.; Scherf, K.A. Quantitation of the immunodominant 33-mer peptide from alpha- ... Approximately 50% of the genetic risk of the disease is explained by the HLA class II region [21], and the haplotypes HLA-DR3- ...
Cited in 3 publications. View Rabbit Polyclonal anti-RRM2 Antibody (NBP1-31661). Validated Applications: WB, ICC/IF, IHC. Validated Species: Human, Mouse, Rat + more.

No FAQ available that match "hla dq alpha chains"

No images available that match "hla dq alpha chains"